s6y

Adaptive Biotechnologies Corp

Nasdaq
ADPT
CIK
1478320
Industry
Biological Products, (No Diagnostic Substances)
Based in
Seattle, Washington
Incorporated in
Washington
Fiscal year ends
December 31
SEC filer category
Large accelerated filer
Employer ID (EIN)
27-0907024
Formerly
Adaptive TCR Corp

About

AI summary. This paragraph was summarized by AI from the company’s annual report. It may contain mistakes: check it against the source. How it was written

Adaptive Biotechnologies Corp is an immune medicine company whose platform uses proprietary sequencing, computational biology and machine learning to read the genetic code of T cell and B cell receptors. It is organized into two businesses. The MRD business offers clonoSEQ, a next-generation sequencing assay that detects and monitors minimal residual disease in lymphoid cancers. It is provided as a clinical diagnostic test for clinicians and, through MRD Pharma, to biopharmaceutical partners for use in clinical trials. clonoSEQ is FDA-authorized for multiple myeloma, B cell acute lymphoblastic leukemia and chronic lymphocytic leukemia, and is available as a laboratory developed test for other lymphoid cancers. The Immune Medicine business offers immune receptor sequencing, licensing of proprietary TCR-antigen data, prediction models and target discovery, including work in autoimmune diseases.

Source: the Business section of the company’s 10-K filed Feb 26, 2026.

Key figures

Fiscal year to Dec 2025 Dec 2024 Dec 2023 Dec 2022 Dec 2021
Revenue $277.0M$179.0M$170.3M$185.3M$154.3M
Operating income −$57.1M−$162.5M−$227.0M−$200.2M−$209.0M
Net income −$59.5M−$159.5M−$225.2M−$200.2M−$207.3M
Diluted EPS −$0.39−$1.08−$1.56−$1.40−$1.48
Cash from operations −$46.0M−$95.2M−$156.3M−$183.9M−$192.7M
Total assets $512.7M$539.4M$661.1M$856.6M$923.3M
Shareholders’ equity $218.8M$202.7M$308.4M$464.2M$604.0M

From the company’s annual reports to the SEC. Each year links to its report.

Name Role As of
Bobulsky Susan Chief Commercial Officer, MRD
Rubinstein Julie President and COO
Robins Chad M CEO and Chairman, Director
Lo Francis Chief People Officer
Owen Katey Einterz Director
Hershberg Robert Director

All 12 · How this list is made

Name Stake As of
Viking Global Investors LP 18.8%

How this list is made

Financials 30

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-Q Quarterly Report for period ending Jun 30, 2024

All 30 financials filings

News 72

  1. 8-K Financial results
  2. 8-K Financial results; Director or officer change
  3. 8-K Material agreement; Material agreement ended; New debt or obligation; Unregistered share sale; Other events
  4. 8-K Other events
  5. 8-K Shareholder vote results
  6. 8-K Financial results
  7. 8-K Financial results
  8. 8-K Financial results; Regulation FD disclosure
  9. 8-K Other events
  10. 8-K Financial results

All 72 news filings

Ownership 672

  1. 4 Bobulsky Susan: Change in insider ownership
  2. 4 Rubinstein Julie: Change in insider ownership
  3. 144 Robins Chad M: Notice of proposed sale of restricted stock
  4. 144 Bobulsky Susan: Notice of proposed sale of restricted stock
  5. 4 Robins Chad M: Change in insider ownership
  6. 4 Rubinstein Julie: Change in insider ownership
  7. 4 Rubinstein Julie: Change in insider ownership
  8. 4 Rubinstein Julie: Change in insider ownership
  9. 4 Rubinstein Julie: Change in insider ownership
  10. 4 Rubinstein Julie: Change in insider ownership

All 672 ownership filings

Prospectus 19

  1. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  2. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  3. 424B7 Prospectus filed pursuant to Rule 424(b)(7)
  4. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  5. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  6. S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
  7. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  8. S-1/A General form of registration statement for all companies including face-amount certificate companies
  9. S-1 General form of registration statement for all companies including face-amount certificate companies
  10. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

All 19 prospectus filings

Proxies 16

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements
  3. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  4. DEF 14A Definitive proxy statements
  5. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  6. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  7. DEF 14A Definitive proxy statements
  8. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  9. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  10. DEF 14A Definitive proxy statements

All 16 proxies filings

Other 30

  1. ARS Annual report to security holders
  2. ARS Annual report to security holders
  3. ARS Annual report to security holders
  4. ARS Annual report to security holders
  5. EFFECT Notice of Effectiveness
  6. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  7. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  8. UPLOAD Letter (PDF)
  9. EFFECT Notice of Effectiveness
  10. CERT Certification by an exchange approving securities for listing

All 30 other filings

Others in Biological Products, (No Diagnostic Substances)

Every company in this industry